Trillium nets $51.8mm through public sale of common and preferred shares

Trillium Therapeutics Inc. (immuno-oncology) netted $51.8mm through the public sale of common and preferred shares. The company issued 1.75mm common shares (including the overallotment) at $19.50, and to existing shareholders whose purchase of common shares would result in beneficial ownership exceeding 4.99%, issued 1.1mm Series II non-voting preferred shares (convertible into common). Proceeds will fund development of SIRPaFc, a fusion protein in IND-enabling studies for acute myeloid leukemia and other blood cancers.